blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3325671

EP3325671 - METHODS FOR USING LONG SSDNA POLYNUCLEOTIDES AS PRIMERS IN PCR ASSAYS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.09.2023
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  23.09.2022
FormerGrant of patent is intended
Status updated on  02.06.2022
FormerExamination is in progress
Status updated on  04.04.2022
FormerGrant of patent is intended
Status updated on  15.02.2022
FormerExamination is in progress
Status updated on  19.06.2019
FormerRequest for examination was made
Status updated on  27.04.2018
FormerThe international publication has been made
Status updated on  20.01.2018
Formerunknown
Status updated on  01.09.2017
Most recent event   Tooltip12.07.2024Lapse of the patent in a contracting state
New state(s): IE		published on 14.08.2024  [2024/33]
Applicant(s)For all designated states
Biodynamics SRL
Av. de Mayo 1370 piso 15 (Torre)
Ciudad de Buenos Aires (1085) / AR
[2022/29]
Former [2018/22]For all designated states
Mautner, Martín Eduardo
Av. de Mayo 975 Floor 5
Buenos Aires, 1 084 / AR
Inventor(s)01 / MAUTNER, Martín Eduardo
Av. de Mayo 975 Floor 5
Buenos Aires, 1 084 / AR
 [2018/22]
Representative(s)López Camba, Emilia
SILEX IP
Glorieta Rubén Darío, 4
28020 Madrid / ES
[N/P]
Former [2022/43]López Camba, Emilia
SILEX IP
Poeta Joan Maragall, 9, Esc. Izq., 3º Izq.
28020 Madrid / ES
Former [2018/22]Monzón de la Flor, Luis Miguel
Poeta Joan Maragall, 9
esc. Izq 3º Izq.
28020 Madrid / ES
Application number, filing date17755066.210.07.2017
[2018/22]
WO2017EP67189
Priority number, dateUS201662361184P12.07.2016         Original published format: US 201662361184 P
US20161528385103.10.2016         Original published format: US201615283851
[2018/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018011101
Date:18.01.2018
Language:EN
[2018/03]
Type: A1 Application with search report 
No.:EP3325671
Date:30.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 18.01.2018 takes the place of the publication of the European patent application.
[2018/22]
Type: B1 Patent specification 
No.:EP3325671
Date:26.10.2022
Language:EN
[2022/43]
Search report(s)International search report - published on:EP18.01.2018
ClassificationIPC:C12Q1/6858, C12Q1/686
[2022/08]
CPC:
C12Q1/686 (EP,US); C12Q1/6858 (EP,US)
C-Set:
C12Q1/6858, C12Q2525/204, C12Q2531/113, C12Q2537/143 (EP,US);
C12Q1/686, C12Q2525/204, C12Q2537/143 (US,EP)
Former IPC [2020/01]C12Q1/686
Former IPC [2018/22]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/22]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR VERWENDUNG LANGER SSDNA-POLYNUKLEOTIDE ALS PRIMER BEI PCR-TESTS[2018/22]
English:METHODS FOR USING LONG SSDNA POLYNUCLEOTIDES AS PRIMERS IN PCR ASSAYS[2018/22]
French:PROCÉDÉS D'UTILISATION DE LONGS POLYNUCLÉOTIDES D'ADNSB COMME AMORCES DANS DES DOSAGES PAR PCR[2018/22]
Entry into regional phase23.02.2018National basic fee paid 
23.02.2018Designation fee(s) paid 
23.02.2018Examination fee paid 
Examination procedure25.01.2018Amendment by applicant (claims and/or description)
25.01.2018Date on which the examining division has become responsible
23.02.2018Examination requested  [2018/22]
25.06.2019Despatch of a communication from the examining division (Time limit: M04)
16.08.2019Reply to a communication from the examining division
08.01.2020Despatch of a communication from the examining division (Time limit: M04)
29.04.2020Reply to a communication from the examining division
19.03.2021Despatch of communication that the application is refused, reason: substantive examination {1}
16.02.2022Communication of intention to grant the patent
01.04.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
03.06.2022Communication of intention to grant the patent
15.09.2022Fee for grant paid
15.09.2022Fee for publishing/printing paid
15.09.2022Receipt of the translation of the claim(s)
Appeal following examination18.05.2021Appeal received
18.05.2021Payment of appeal fee
18.05.2021Statement of grounds filed
05.07.2021Interlocutory revision of appeal
Opposition(s)27.07.2023No opposition filed within time limit [2023/40]
Fees paidRenewal fee
30.07.2019Renewal fee patent year 03
21.07.2020Renewal fee patent year 04
28.07.2021Renewal fee patent year 05
29.07.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
IT26.10.2022
LT26.10.2022
LV26.10.2022
MC26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
GB10.07.2023
IE10.07.2023
LU10.07.2023
[2024/33]
Former [2024/26]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
IT26.10.2022
LT26.10.2022
LV26.10.2022
MC26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
GB10.07.2023
LU10.07.2023
Former [2024/24]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
MC26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
GB10.07.2023
LU10.07.2023
Former [2024/18]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
MC26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
LU10.07.2023
Former [2024/14]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
MC26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/51]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/38]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/37]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/35]AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/34]AT26.10.2022
DK26.10.2022
EE26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/33]AT26.10.2022
DK26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/25]AT26.10.2022
ES26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RS26.10.2022
SE26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/23]AT26.10.2022
ES26.10.2022
FI26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
SE26.10.2022
NO26.01.2023
GR27.01.2023
PT27.02.2023
Former [2023/22]AT26.10.2022
ES26.10.2022
FI26.10.2022
LT26.10.2022
NL26.10.2022
SE26.10.2022
NO26.01.2023
PT27.02.2023
Former [2023/20]LT26.10.2022
NL26.10.2022
NO26.01.2023
Former [2023/17]NL26.10.2022
Cited inInternational search[A]WO2011023131  (BEIJING PEOPLESPOT TECHNOLOGY CO LTD [CN], et al) [A] 1-23 * abstract ** figures 1-3 *;
 [XDI]US2013115605  (MERK HELMUT [DE], et al) [XD] 1-7,9,10,12,13,15-17,19-23 * paragraph [0029] * * claim 3 * * figures 1-2 * [I] 8,11,14,18;
 [A]US2014066322  (ALMEIDA JAMIE L [US], et al) [A] 1-23 * abstract * * claims 1, 7-16 *;
 [XI]  - TRICHAS GEORGIOS ET AL, "Use of the viral 2A peptide for bicistronic expression in transgenic mice", BMC BIOLOGY, BIOMED CENTRAL, LONDON, GB, GB, (20080915), vol. 6, no. 1, doi:10.1186/1741-7007-6-40, ISSN 1741-7007, page 40, XP021044858 [X] 1-7,9,10,12,13,15-17,19-23 * abstract * [I] 8,11,14,18

DOI:   http://dx.doi.org/10.1186/1741-7007-6-40
 [XI]  - BARIK S ED - DUCRY ET AL, "Site-directed mutagenesis in vitro by megaprimer PCR", ANTIBODY-DRUG CONJUGATES IN: METHODS IN MOLECULAR BIOLOGY , ISSN 1064-3745; VOL. 1045; [METHODS IN MOLECULAR BIOLOGY , ISSN 1064-3745; VOL. 1045], HUMANA PRESS, US, (19960101), vol. 57, ISSN 1064-3745, ISBN 978-1-62703-541-5, pages 203 - 215, XP009135639 [X] 1-7,10,13,16,17,19-23 * Introduction * * figure 1 * * item 3.2.2.1. on page 208 * [I] 8,11,14,18
ExaminationUS2015232929
    - CASTRO ÁLVARO ET AL, "Synthesis of an artificialVitis viniferamiRNA 319e using overlapping long primers and its application for gene silencing", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, (20160710), vol. 233, doi:10.1016/J.JBIOTEC.2016.06.028, ISSN 0168-1656, pages 200 - 210, XP029674977

DOI:   http://dx.doi.org/10.1016/j.jbiotec.2016.06.028
    - WOODDELL C I ET AL, "USE OF ASYMETRIC PCR TO GENERATE LONG PRIMERS AND SINGLE-STRANDED DNA FOR INCORPORATING CROSS-LINKING ANALOGS INTO SPECIFIC SITES IN A DNA PROBE", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, (19960901), vol. 6, no. 9, ISSN 1088-9051, pages 886 - 892, XP009067846
by applicantDE3834636
 US5364759
 US5582979
 US6479235
 US6743905
 US2013115605
 US2016168644
    - LITT; LUTY, Am J. Hum Genet, (19890000), vol. 3, no. 4, pages 599 - 605
    - TAUTZ, D, NAR, (19890000), vol. 17, pages 6463 - 6471
    - WEBER; MAY, Am J Hum Genet, (19890000), vol. 44, pages 388 - 396
    - EDWARDS, A. et al., Am. J. Hum. Genet., (19910000), vol. 49, pages 746 - 756
    - HAMMOND, H. A. et al., Am. J. Hum. Genet, (19940000), vol. 55, pages 175 - 189
    - FREGEAU, C. J.; FOURNEY, R. M., BioTechniques, (19930000), vol. 15, no. 1, pages 100 - 119
    - SCHUMM, J. W. et al., The Fourth International Symposium on Human Identification, vol. 1993, pages 177 - 187
    - EDWARDS et al., Nucleic Acids Res., (19910000), vol. 19, page 4791
    - CHEN et al., Genomics, (19930000), vol. 15, no. 3, pages 621 - 5
    - HARADA et al., Am. J. Hum. Genet, (19940000), vol. 55, pages 175 - 189
    - COMINGS et al., Genomics, (19950000), vol. 29, no. 2, pages 390 - 6
    - UTAH, "Marker Development Group", Am. J. Genet, (19950000), vol. 57, pages 619 - 628
    - JURKA; PETHIYAGODA, J. Mol. Evol., (19950000), vol. 40, pages 120 - 126
    - WHITAKER JP; CLAYTON TM; URQUHART AJ et al., BioTechniques, (19950000), vol. 18, pages 670 - 677
    - BUTLER JM; SHEN Y; MCCORD BR., J Forensic Sci, (20030000), page 48
    - TRICHAS G.; BEGBIE J.; SRNIVAS S., BCM Biology, (20080000), vol. 6, page 40
    - VILJOEN C.D.; THOMPSON G.G.; SREENIVASAN S., Gene, (20130301), vol. 516, no. 1, pages 143 - 5
    - GIBSON D., Nucleic Acids Res, (20090000), vol. 37, no. 20, pages 6984 - 6990
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.